Prednisone Completed Phase 2 / 3 Trials for Prostate Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2 / 3
clinicaltrials.gov IdentifierTitleDrugs
NCT01867710Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
NCT00642018A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer
NCT01619813Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
NCT01204710A Study of Olaratumab (IMC-3G3) in Prostate Cancer
NCT00436956AZD2171 to Treat Prostate Cancer
NCT01051570Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
NCT01393730Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
NCT02097303Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
NCT00087165GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer
NCT00268593Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer
NCT00258388Docetaxel and Prednisone With or Without OGX-011 in Treating Patients With Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
NCT00466440A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients
NCT00350051ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer
NCT00416533Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00072930MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
NCT00124566Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
NCT00924469A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
NCT01088529Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
NCT00627354Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00683475A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
NCT01946165Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
NCT00182741Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer
NCT01549951Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer